All Stories

  1. Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses
  2. A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody
  3. Development of a novel equine influenza virus live-attenuated vaccine
  4. Antigenicity of the 2015–2016 seasonal H1N1 human influenza virus HA and NA proteins
  5. Oxygen-dependent changes in lung development do not affect epithelial infection with influenza A virus
  6. Influenza A Virus Studies in a Mouse Model of Infection
  7. Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo
  8. The K186E Amino Acid Substitution in the Canine Influenza Virus H3N8 NS1 Protein Restores Its Ability To Inhibit Host Gene Expression
  9. A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses
  10. Functional Evolution of Influenza Virus NS1 Protein in Currently Circulating Human 2009 Pandemic H1N1 Viruses
  11. Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus
  12. A live-attenuated influenza vaccine for H3N2 canine influenza virus
  13. Avian Interferons and Their Antiviral Effectors
  14. Lassa Virus Reverse Genetics
  15. Reverse Genetics of Influenza B Viruses
  16. Development of Recombinant Arenavirus-Based Vaccines
  17. Plasmid-Based Reverse Genetics of Influenza A Virus
  18. 46: Gestational age differences in susceptibility of the human placenta to viral infection
  19. Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines
  20. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein
  21. Reverse Genetics Approaches for the Development of Influenza Vaccines
  22. NS1 Protein Amino Acid Changes D189N and V194I Affect Interferon Responses, Thermosensitivity, and Virulence of Circulating H3N2 Human Influenza A Viruses
  23. Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine
  24. Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication
  25. Mutations at highly conserved residues in influenza A(H1N1)pdm09 virus affect neuraminidase activity
  26. NS1 Protein Mutation I64T Affects Interferon Responses and Virulence of Circulating H3N2 Human Influenza A Viruses
  27. Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses
  28. Replication-Competent Influenza A Viruses Expressing Reporter Genes
  29. Mutations Designed by Ensemble Defect to Misfold Conserved RNA Structures of Influenza A Segments 7 and 8 Affect Splicing and Attenuate Viral Replication in Cell Culture
  30. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines
  31. Development and applications of single-cycle infectious influenza A virus (sciIAV)
  32. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines
  33. Replication-competent fluorescent-expressing influenza B virus
  34. Replication-Competent Influenza A and B Viruses Expressing a Fluorescent Dynamic Timer Protein for In Vitro and In Vivo Studies
  35. Reverse Genetics Approaches to Control Arenavirus
  36. Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA)
  37. Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines
  38. An improved method for estimating antibody titers in microneutralization assay using green fluorescent protein
  39. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines
  40. Lymphocytic Choriomeningitis Virus Differentially Affects the Virus-Induced Type I Interferon Response and Mitochondrial Apoptosis Mediated by RIG-I/MAVS
  41. Replication-competent influenza A viruses expressing a red fluorescent protein
  42. Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization
  43. Innate Immunity against RNA viruses☆
  44. Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine
  45. Comparison of Serum Hemagglutinin and Neuraminidase Inhibition Antibodies After 2010-2011 Trivalent Inactivated Influenza Vaccination in Healthcare Personnel
  46. Cytomegalovirus-mediated activation of pyrimidine biosynthesis drives UDP–sugar synthesis to support viral protein glycosylation
  47. The Specialized Proresolving Mediator 17-HDHA Enhances the Antibody-Mediated Immune Response against Influenza Virus: A New Class of Adjuvant?
  48. The Human Cytomegalovirus UL26 Protein Antagonizes NF- B Activation
  49. Corrigendum to “Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies” [J. Virol. Methods 197 (2014) 47–50)]
  50. Induction of CD8 T Cell Heterologous Protection by a Single Dose of Single-Cycle Infectious Influenza Virus
  51. Influenza A and B Virus Intertypic Reassortment through Compatible Viral Packaging Signals
  52. Influenza A Virus Attenuation by Codon Deoptimization of the NS Gene for Vaccine Development
  53. Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies
  54. Inhibition of Arenavirus by A3, a Pyrimidine Biosynthesis Inhibitor
  55. Rescue of Recombinant Newcastle Disease Virus from cDNA
  56. Crystallographic Fragment Screening and Structure-Based Optimization Yields a New Class of Influenza Endonuclease Inhibitors
  57. Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
  58. Protection against Lethal Influenza with a Viral Mimic
  59. Arenavirus reverse genetics for vaccine development
  60. D471G Mutation in LCMV-NP Affects Its Ability to Self-associate and Results in a Dominant Negative Effect in Viral RNA Synthesis
  61. Arenavirus Nucleoproteins Prevent Activation of Nuclear Factor Kappa B
  62. Arenavirus Nucleoprotein Targets Interferon Regulatory Factor-Activating Kinase IKK 
  63. Self-Association of Lymphocytic Choriomeningitis Virus Nucleoprotein Is Mediated by Its N-Terminal Region and Is Not Required for Its Anti-Interferon Function
  64. Host-Range Restriction of Vaccinia Virus E3L Deletion Mutant Can Be Overcome In Vitro, but Not In Vivo, by Expression of the Influenza Virus NS1 Protein
  65. The C-Terminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of the Type I Interferon Response
  66. Host- and Strain-Specific Regulation of Influenza Virus Polymerase Activity by Interacting Cellular Proteins
  67. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease
  68. Corrigendum to “Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes” [Virology 410 (2011) 240–247]
  69. Maternal Influenza Viral Infection Causes Schizophrenia-Like Alterations of 5-HT2A and mGlu2 Receptors in the Adult Offspring
  70. Use of Single-Cycle Infectious Lymphocytic Choriomeningitis Virus To Study Hemorrhagic Fever Arenaviruses
  71. Regulation of PURA gene transcription by three promoters generating distinctly spliced 5-prime leaders: a novel means of fine control over tissue specificity and viral signals
  72. Inhibition of the Type I Interferon Antiviral Response During Arenavirus Infection
  73. Induction of Type I Interferon Secretion through Recombinant Newcastle Disease Virus Expressing Measles Virus Hemagglutinin Stimulates Antibody Secretion in the Presence of Maternal Antibodies
  74. Glycine 184 in Nonstructural Protein NS1 Determines the Virulence of Influenza A Virus Strain PR8 without Affecting the Host Interferon Response
  75. Generation of Recombinant Influenza Virus from Plasmid DNA
  76. Murine Coronavirus Delays Expression of a Subset of Interferon-Stimulated Genes
  77. Hemagglutinin-Pseudotyped Green Fluorescent Protein-Expressing Influenza Viruses for the Detection of Influenza Virus Neutralizing Antibodies
  78. Thogoto virus ML protein is a potent inhibitor of the interferon regulatory factor-7 transcription factor
  79. Strong interferon-inducing capacity of a highly virulent variant of influenza A virus strain PR8 with deletions in the NS1 gene
  80. Identification of Amino Acid Residues Critical for the Anti-Interferon Activity of the Nucleoprotein of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus
  81. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation
  82. Influenza B Virus Ribonucleoprotein Is a Potent Activator of the Antiviral Kinase PKR
  83. Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses
  84. A novel high‐throughput cell‐based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery
  85. Mice Lacking the ISG15 E1 Enzyme UbE1L Demonstrate Increased Susceptibility to both Mouse-Adapted and Non-Mouse-Adapted Influenza B Virus Infection
  86. Influenza B Virus NS1-Truncated Mutants: Live-Attenuated Vaccine Approach
  87. 236 SARS-coronavirus inhibits interferon induction both at pre- and post-transcriptional levels
  88. 292 p53 Transcriptionally activates IRF9 to enhance antiviral immunity
  89. Transcriptional role of p53 in interferon-mediated antiviral immunity
  90. Crimean‐Congo hemorrhagic fever virus delays activation of the innate immune response
  91. Distinct RIG-I and MDA5 Signaling by RNA Viruses in Innate Immunity
  92. Differential Inhibition of Type I Interferon Induction by Arenavirus Nucleoproteins
  93. Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus
  94. Recombinant influenza virus vectors
  95. The intracellular sites of early replication and budding of SARS-coronavirus
  96. Inhibition of the Alpha/Beta Interferon Response by Mouse Hepatitis Virus at Multiple Levels
  97. Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines
  98. Multiple Anti-Interferon Actions of the Influenza A Virus NS1 Protein
  99. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene
  100. Identification of Cellular Interaction Partners of the Influenza Virus Ribonucleoprotein Complex and Polymerase Complex Using Proteomic-Based Approaches
  101. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists
  102. Inhibition of Retinoic Acid-Inducible Gene I-Mediated Induction of Beta Interferon by the NS1 Protein of Influenza A Virus
  103. Inhibition of the Type I Interferon Response by the Nucleoprotein of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus
  104. Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling
  105. Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector
  106. 7a Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates p38 Mitogen-Activated Protein Kinase
  107. Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses
  108. Inhibition of Beta Interferon Induction by Severe Acute Respiratory Syndrome Coronavirus Suggests a Two-Step Model for Activation of Interferon Regulatory Factor 3
  109. Thogoto virus ML protein suppresses IRF3 function
  110. Mucosal immunization with attenuated Shigella flexneri harboring an influenza hemagglutinin DNA vaccine protects mice against a lethal influenza challenge
  111. The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3